Ariel I M, Padula G
J Surg Oncol. 1982 Jul;20(3):151-6. doi: 10.1002/jso.2930200304.
Forty patients with asymptomatic metastatic cancer to the liver discovered at the time of laparotomy were treated by combined intrahepatic arterial chemotherapy and internal irradiation in the form of 90Yttrium microspheres. One group of 25 patients were treated by a catheter inserted at the time of operation and received 100 mCi; of 90Yttrium microspheres and 5-fluorouracil on a continuing basis. They survived an average of 26 mo (varying from 9 to 60 mo). The second series of 15 patients referred after surgery were treated by the percutaneous insertion of the catheter into the hepatic artery and received a bolus of combined chemotherapy consisting of PlatinolTM, Methotrexate, and 5-fluorouracil. They survived an average of 31 mo, which varied from 12 to 60 mo. The dose of 100 mCi of 90Yttrium was well tolerated by the liver. Prospective studies are in progress, limiting the treatment to the internal irradiation to determine its precise role in the overall treatment of metastatic cancer to the liver.
40例在剖腹手术时发现有肝脏无症状转移癌的患者接受了肝内动脉化疗联合钇-90微球内照射治疗。一组25例患者在手术时插入导管，持续接受100毫居里的钇-90微球和5-氟尿嘧啶治疗。他们的平均生存期为26个月（9至60个月不等）。第二组15例术后转诊的患者通过经皮将导管插入肝动脉，接受了由顺铂、甲氨蝶呤和5-氟尿嘧啶组成的联合化疗推注。他们的平均生存期为31个月，从12至60个月不等。100毫居里的钇-90剂量肝脏耐受性良好。前瞻性研究正在进行中，将治疗局限于内照射以确定其在肝脏转移癌整体治疗中的精确作用。
